Actelion announces change in its Board of Directors
Actelion Ltd (SIX: ATLN) announced today that Dr. Elias Zerhouni has resigned from Actelion's Board of Director at the end of 2010. Dr. Zerhouni will focus on his new role as President, Global Research and Development at Sanofi-aventis, an executive function he is assuming as of the beginning of 2011.
- (1888PressRelease) January 04, 2011 - Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented:"We would like to thank Dr. Zerhouni for his valuable contribution as a Board member. We have benefited from his vast scientific managerial and strategic experience. We wish him success in his new executive role that leads to him leaving our Board."
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug TracleerŪ, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets TracleerŪ through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMIŪ).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam